Medications Development for the Treatment of Cannabis Related Disorders
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this application is to test the neurobehavioral mechanisms and
effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
Phase:
Phase 1
Details
Lead Sponsor:
University of Virginia
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Analgesics Aprepitant Fosaprepitant Molecular Mechanisms of Pharmacological Action Nicotine Peripheral Nervous System Agents